```html

Non‑Alcoholic Steatohepatitis (NASH) – A Complete Medical Guide

Overview

Non‑alcoholic steatohepatitis (NASH) is an advanced form of non‑alcoholic fatty liver disease (NAFLD) in which excess fat accumulation in the liver is accompanied by inflammation and liver cell injury. Over time, this can progress to fibrosis (scarring), cirrhosis, and even liver cancer.

• Who it affects: Adults of any age, but it is most common in middle‑aged and older adults (40‑70 years). Women, especially after menopause, and men with central obesity are at higher risk.
• Prevalence: NAFLD affects roughly 25‑30 % of the global adult population. Of those, about 20‑30 % develop NASH, meaning an estimated 5‑8 % of adults worldwide have NASH (≈ 300‑500 million people). In the United States, prevalence is higher—approximately 10‑12 % of adults and up to 20‑25 % of people with type 2 diabetes (T2DM) (CDC, 2023; NIH).

Because NASH often has no early symptoms, it is frequently discovered incidentally during routine blood work or imaging for unrelated reasons.

Symptoms

Early NASH may be silent. When symptoms appear, they tend to be nonspecific and can be mistaken for other conditions.

Common signs and symptoms

• Fatigue or low energy – persistent tiredness not explained by lifestyle.
• Right‑upper‑quadrant abdominal discomfort – a vague ache under the rib cage where the liver sits.
• Unexplained weight loss – despite stable diet and activity.
• Loss of appetite – may accompany early liver dysfunction.
• Joint or muscle pain – often linked to metabolic syndrome.

Advanced disease symptoms

• Jaundice – yellowing of the skin and eyes, indicating impaired bilirubin processing.
• Hepatomegaly – an enlarged liver palpable on exam.
• Spider angiomas, palmar erythema, or bruising – signs of chronic liver disease.
• Ascites – fluid accumulation in the abdomen.
• Encephalopathy – confusion or altered mental status due to toxin buildup.
• Unexplained itching (pruritus) – often due to bile salt retention.

Because symptoms overlap with many other conditions, lab testing and imaging are essential for an accurate diagnosis.

Causes and Risk Factors

NASH is not caused by alcohol (by definition) but results from a combination of metabolic stressors that promote fat buildup and inflammation in the liver.

Primary causes

• Insulin resistance – leads to increased free fatty acids delivered to the liver.
• Obesity, especially visceral (central) obesity – excess adipose tissue releases inflammatory cytokines.
• Dyslipidemia – high triglycerides and low HDL cholesterol fuel hepatic fat accumulation.
• Genetic predisposition – variants in the PNPLA3, TM6SF2, and MBOAT7 genes increase susceptibility.
• Gut microbiome alterations – bacterial endotoxins can trigger liver inflammation.

Risk factors

• Body mass index (BMI) ≥ 30 kg/m² (obesity) or BMI 25‑29.9 kg/m² with metabolic syndrome.
• Type 2 diabetes mellitus (about 30‑50 % of T2DM patients have NASH).
• Elevated triglycerides (≥ 150 mg/dL) or low HDL‑C.
• Polycystic ovary syndrome (PCOS) – associated with insulin resistance.
• Older age (> 50 years) and male sex (though post‑menopausal women catch up).
• Certain medications: long‑term corticosteroids, amiodarone, methotrexate, tamoxifen.
• Rapid weight loss or malnutrition (e.g., after bariatric surgery), which can worsen liver injury.

Diagnosis

Diagnosing NASH requires a stepwise approach: ruling out other liver diseases, establishing the presence of steatosis, and confirming inflammation/fibrosis.

Initial evaluation

• History & physical exam – assess alcohol intake, medication list, metabolic risk factors.
• Blood tests:
  • ALT and AST – usually mildly elevated (ALT > AST).
  • Alkaline phosphatase, GGT – may be raised.
  • Complete metabolic panel – to evaluate glucose, lipids, bilirubin.
  • Serologic tests to exclude viral hepatitis (HBV, HCV), autoimmune hepatitis, Wilson disease, hemochromatosis.
• Non‑invasive scoring systems – e.g., NAFLD Fibrosis Score (NFS), FIB‑4 index. These combine age, BMI, liver enzymes, platelet count, and glucose to estimate fibrosis risk.

Imaging studies

• Ultrasound – first‑line; detects moderate‑to‑severe steatosis but cannot differentiate NASH from simple fatty liver.
• Transient elastography (FibroScan) – measures liver stiffness (fibrosis) and controlled attenuation parameter (CAP) for steatosis. Widely used in clinics.
• Magnetic resonance imaging–based techniques – MRI‑PDFF quantifies fat; MR elastography accurately stages fibrosis.

Liver biopsy (gold standard)

Indicated when non‑invasive tests are inconclusive or when treatment decisions require precise staging. A 14‑gauge core is examined for:

• Steatosis (> 5 % hepatocytes with fat).
• Ballooning degeneration of hepatocytes.
• Inflammatory infiltrates.
• Fibrosis stage (F0‑F4).

Biopsy carries a small bleeding risk (≈ 0.5‑1 %) and is usually performed by an experienced hepatologist.

Treatment Options

There is currently no FDA‑approved drug specifically for NASH, but several therapies are in advanced clinical trials. Management combines lifestyle modification, control of metabolic risk factors, and off‑label pharmacologic agents.

Lifestyle interventions (first‑line)

• Weight loss – 7‑10 % reduction in body weight can improve steatosis and inflammation; > 15 % may also reverse fibrosis (Cleveland Clinic, 2022).
• Diet – Mediterranean diet (rich in olive oil, nuts, fish, vegetables, low in refined carbs) is associated with lower liver fat.
• Physical activity – ≥ 150 minutes/week of moderate aerobic exercise (e.g., brisk walking) plus resistance training 2‑3 times/week.

Medical management of comorbidities

• Type 2 diabetes – GLP‑1 receptor agonists (e.g., semaglutide) have shown reduction in liver fat and NASH resolution in phase III trials (NIH, 2023).
• Lipid control – Statins are safe in NAFLD/NASH and lower cardiovascular risk; they do not directly treat liver disease but are recommended.
• Hypertension – ACE inhibitors or ARBs may have modest antifibrotic effects.

Pharmacologic agents used off‑label or under investigation

• Vitamin E (800 IU/day) – improves histology in non‑diabetic adults with NASH (AASLD guideline, 2022). Caution: risk of hemorrhagic stroke with long‑term high dose.
• Pioglitazone (30 mg daily) – improves insulin sensitivity and liver histology, especially in diabetics. Monitor for weight gain and bladder cancer risk.
• Obeticholic acid – a farnesoid X receptor agonist; phase III REGENERATE trial showed fibrosis improvement but increased LDL‑C; FDA decision pending.
• Emerging agents – e.g., elafibranor (PPAR‑α/δ agonist), selonsertib (ASK‑1 inhibitor), and many others in Phase II/III trials.

Procedural options for advanced disease

• Bariatric surgery – leads to sustained weight loss; can improve NASH and even reverse fibrosis in many patients.
• Liver transplantation – reserved for decompensated cirrhosis or hepatocellular carcinoma (HCC) when other therapies fail.

Living with NASH (Non‑Alcoholic Steatohepatitis)

Successful long‑term management hinges on daily habits and regular monitoring.

Practical daily‑management tips

• Set realistic weight‑loss goals – aim for 0.5‑1 kg per week; use food logs or apps.
• Choose whole, unprocessed foods – prioritize vegetables, legumes, whole grains, fish, and nuts.
• Limit added sugars and refined carbs – avoid sugary drinks, desserts, white bread.
• Watch portion sizes of saturated fats – swap butter with olive oil, choose lean meats.
• Stay hydrated – water, herbal teas; limit sugary beverages and excessive alcohol (even small amounts can worsen liver injury).
• Exercise routine – mix cardio (walking, cycling) with strength training; be consistent.
• Medication adherence – take prescribed meds (e.g., vitamin E, GLP‑1 agonist) exactly as directed.
• Regular follow‑up – labs every 6‑12 months, FibroScan annually or per provider recommendation.
• Vaccinations – hepatitis A and B, annual flu, COVID‑19, and pneumococcal vaccines as advised.
• Stress management – chronic stress worsens insulin resistance; consider yoga, mindfulness, or counseling.

Prevention

Because NASH is closely linked to lifestyle‑related metabolic disorders, prevention focuses on maintaining a healthy weight and metabolic health.

• Maintain BMI < 25 kg/m²; if overweight, aim for a 5‑10 % weight loss.
• Adopt a Mediterranean‑style diet rich in fiber and omega‑3 fatty acids.
• Exercise ≥ 150 minutes/week of moderate‑intensity activity.
• Control blood sugar; early treatment of pre‑diabetes with diet, exercise, or metformin.
• Manage dyslipidemia with diet, statins, or lipid‑lowering agents as prescribed.
• Avoid excessive alcohol (≤ 1 drink/day for women, ≤ 2 for men) and limit hepatotoxic medications.
• Screen high‑risk individuals (obesity, T2DM, metabolic syndrome) with ALT/AST and, if abnormal, proceed to imaging.

Complications

If untreated, NASH can progress along a continuum of liver injury.

• Fibrosis & cirrhosis – irreversible scarring; can lead to portal hypertension, variceal bleeding, and liver failure.
• Hepatocellular carcinoma (HCC) – risk rises markedly in cirrhotic NASH; annual incidence ~1‑2 %.
• Decompensated liver disease – ascites, hepatic encephalopathy, coagulopathy.
• Cardiovascular disease – leading cause of death in NAFLD/NASH patients; shares common risk factors.
• Kidney disease – increased prevalence of chronic kidney disease (CKD) in NASH.
• Extra‑hepatic malignancies – higher rates of colorectal and pancreatic cancer reported.

When to Seek Emergency Care

References

1. Mayo Clinic. Non‑alcoholic fatty liver disease (NAFLD). https://www.mayoclinic.org (accessed May 2026).
2. Centers for Disease Control and Prevention (CDC). Prevalence of NAFLD and NASH in the United States, 2023. https://www.cdc.gov.
3. National Institutes of Health (NIH). Emerging therapies for NASH – 2023 update. https://www.nih.gov.
4. American Association for the Study of Liver Diseases (AASLD) Guidance on the Diagnosis and Management of NASH, 2022. https://www.aasld.org.
5. Cleveland Clinic. Non‑Alcoholic Fatty Liver Disease (NAFLD) & NASH treatment options. https://my.clevelandclinic.org.
6. World Health Organization. Global health estimates for liver disease, 2022. https://www.who.int.

```